[Pubmed] Long-term impact of newly-proposed clinical obesity on autoimmune disease incidence: insights from the UK Bioba

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6507
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Chrome

[Pubmed] Long-term impact of newly-proposed clinical obesity on autoimmune disease incidence: insights from the UK Bioba

Message par RSS-Bot »


Int J Obes (Lond). 2025 Dec 2. doi: 10.1038/s41366-025-01970-8. Online ahead of print.

ABSTRACT

BACKGROUND/OBJECTIVES: The definition of clinical obesity was newly announced. The aim of our study was to investigate the association of preclinical obesity and clinical obesity either at baseline or determined during follow-ups with the risk of autoimmune diseases (s) incidence.

SUBJECTS/METHODS: Data were collected from 229,190 participants in the UK Biobank. Dysfunctions caused by obesity, in combination with anthropometric parameters, were used to diagnose clinical obesity. Seven prevalent ADs were analysed, including seropositive rheumatoid arthritis (PRA), psoriasis (PSO), multiple sclerosis (MS), systemic lupus erythematosus (SLE), myasthenia gravis (MG), Crohn's disease (CD), and ulcerative colitis (UC). According to obesity and dysfunction status, participants were categorized into six clusters. Time-dependent Cox model was used to compare hazard ratios (HRs) for ADs incidence across six clusters.

RESULTS: In a total of 4938 ADs incidence events over a mean follow-up of 13.3 years, participants in Cluster 6 (clinical obesity at baseline; HR = 2.48, 95% CI: 2.222.78) and Cluster 3 (non-obesity and dysfunction at baseline; HR = 2.16, 95% CI: 1.83-2.55) exhibited the highest multivariable-adjusted mortality risk compared with participants without obesity and dysfunction at baseline and during follow-up (Cluster 1). Specific ADs analyses showed consistently higher incidence risks in Cluster 6, notably in PSO and PRA (HR = 4.31, 95% CI: 3.58-5.19 and HR = 3.63, 95% CI: 2.54-5.18, respectively).

CONCLUSION: Clinical obesity was significantly associated with elevated ADs incidence risk. These findings underscore the importance of early screening and intervention of clinical obesity and dysfunctions due to obesity.

PMID:41326745 | DOI:10.1038/s41366-025-01970-8


Source: https://pubmed.ncbi.nlm.nih.gov/4132674 ... 22+67771e2
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »